Bright Minds Biosciences (CSE: DRUG) this morning enhanced its leadership team. The company appointed two industry executives to key roles within the company, while also adding a member to its scientific advisory board.
Bright Minds has seen the appointment of Jianmin Duan, PhD, appointed to the role of VP of Pharmacology. Duan, a highly experienced pharmaceutical research and development scientist, will lead the preclinical test work conducted by the company. Duan most recently served as director of Preclinical ADMEPK/Pharmacology at Boehringer Ingelheim, where they spent more than twenty years in roles of increasing responsibility.
Thomas Grizzle meanwhile, whom is an experienced toxicologist, will lead the firms efforts on safety and biological effects of its therapeutics. Grizzle specializes in pharmacokinetics, safety pharmacology, project management, and bioanalytical chemistry among other specialties. Grizzle currently holes an MS in Physiology/Biochemistry from North Carolina State University.
Finally, Krista Lanctot, PhD, has joined the firms scientific advisory team. Lanctot is currently a senior scientist at Sunnybrook Research Institute as well as a professor of psychiatry and pharmacology at the University of Toronto. Lanctot, among other items, comes experienced in conducting clinical trials for cognitive and neuropsychiatric symptoms associated with dementia.
Bright Minds last traded at $5.96 on the CSE.
FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
